{"result": {"id": "3b3ad8cd-ef4b-491d-9d18-9f42438b81d9", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>SERTRALINE<|>ORGANIZATION<|>An antidepressant drug that affects serotonin levels and increases vascular sensitivity)\n##\n(\"entity\"<|>FLUVOXAMINE<|>ORGANIZATION<|>An antidepressant drug that affects serotonin levels and increases vascular sensitivity)\n##\n(\"entity\"<|>PAROXETINE<|>ORGANIZATION<|>An antidepressant drug that affects serotonin levels and increases vascular sensitivity)\n##\n(\"entity\"<|>VENLAFAXINE<|>ORGANIZATION<|>An antidepressant drug that affects serotonin levels and increases vascular sensitivity)\n##\n(\"entity\"<|>REBOXETINE<|>ORGANIZATION<|>An antidepressant drug that affects serotonin levels and increases vascular sensitivity)\n##\n(\"entity\"<|>PHENCYCLIDINE<|>ORGANIZATION<|>An antidepressant drug that affects serotonin levels and increases vascular sensitivity)\n##\n(\"entity\"<|>PHENELZINE<|>ORGANIZATION<|>An antidepressant drug that affects serotonin levels and increases vascular sensitivity)\n##\n(\"entity\"<|>DESOGESTREL AND ETHINYL ESTRADIOL<|>ORGANIZATION<|>An oral contraceptive that affects blood volume and RAS system)\n##\n(\"entity\"<|>ETHINYL ESTRADIOL AND CYPROTERONE ACETATE<|>ORGANIZATION<|>An oral contraceptive that affects blood volume and RAS system)\n##\n(\"entity\"<|>DROSPIRENONE AND ETHINYL ESTRADIOL<|>ORGANIZATION<|>An oral contraceptive that affects blood volume and RAS system)\n##\n(\"entity\"<|>BEVACIZUMAB<|>ORGANIZATION<|>A VEGF monoclonal antibody anti-tumor drug that activates RAS and causes vasoconstriction)\n##\n(\"entity\"<|>SUNITINIB<|>ORGANIZATION<|>A tyrosine kinase inhibitor anti-tumor drug that activates RAS and causes vasoconstriction)\n##\n(\"entity\"<|>SORAFENIB<|>ORGANIZATION<|>A tyrosine kinase inhibitor anti-tumor drug that activates RAS and causes vasoconstriction)\n##\n(\"entity\"<|>AXITINIB<|>ORGANIZATION<|>A tyrosine kinase inhibitor anti-tumor drug that activates RAS and causes vasoconstriction)\n##\n(\"entity\"<|>CORTISONE<|>ORGANIZATION<|>A glucocorticoid that enhances RAS effects and causes water retention)\n##\n(\"entity\"<|>PREDNISONE<|>ORGANIZATION<|>A glucocorticoid that enhances RAS effects and causes water retention)\n##\n(\"entity\"<|>PREDNISOLONE<|>ORGANIZATION<|>A glucocorticoid that enhances RAS effects and causes water retention)\n##\n(\"entity\"<|>DEXAMETHASONE<|>ORGANIZATION<|>A glucocorticoid that enhances RAS effects and causes water retention)\n##\n(\"entity\"<|>RECOMBINANT HUMAN ERYTHROPOIETIN<|>ORGANIZATION<|>Promotes endothelin-1 release and reduces nitric oxide synthesis)\n##\n(\"entity\"<|>AZATHIOPRINE<|>ORGANIZATION<|>An immunosuppressant that increases renal vascular endothelin levels)\n##\n(\"entity\"<|>6-MERCAPTOPURINE<|>ORGANIZATION<|>An immunosuppressant that increases renal vascular endothelin levels)\n##\n(\"entity\"<|>CYCLOPHOSPHAMIDE<|>ORGANIZATION<|>An immunosuppressant that increases renal vascular endothelin levels)\n##\n(\"entity\"<|>DIAMMONIUM GLYCYRRHIZINATE<|>ORGANIZATION<|>A licorice extract that inhibits 11β-hydroxysteroid dehydrogenase)\n##\n(\"entity\"<|>COMPOUND LICORICE TABLETS<|>ORGANIZATION<|>Contains licorice extract that inhibits 11β-hydroxysteroid dehydrogenase)\n##\n(\"relationship\"<|>SERTRALINE<|>SYMPATHETIC NERVOUS SYSTEM<|>Sertraline increases vascular sensitivity to sympathetic stimulation<|>7)\n##\n(\"relationship\"<|>FLUVOXAMINE<|>SYMPATHETIC NERVOUS SYSTEM<|>Fluvoxamine increases vascular sensitivity to sympathetic stimulation<|>7)\n##\n(\"relationship\"<|>PAROXETINE<|>SYMPATHETIC NERVOUS SYSTEM<|>Paroxetine increases vascular sensitivity to sympathetic stimulation<|>7)\n##\n(\"relationship\"<|>VENLAFAXINE<|>SYMPATHETIC NERVOUS SYSTEM<|>Venlafaxine increases vascular sensitivity to sympathetic stimulation<|>7)\n##\n(\"relationship\"<|>REBOXETINE<|>SYMPATHETIC NERVOUS SYSTEM<|>Reboxetine increases vascular sensitivity to sympathetic stimulation<|>7)\n##\n(\"relationship\"<|>PHENCYCLIDINE<|>SYMPATHETIC NERVOUS SYSTEM<|>Phencyclidine increases vascular sensitivity to sympathetic stimulation<|>7)\n##\n(\"relationship\"<|>PHENELZINE<|>SYMPATHETIC NERVOUS SYSTEM<|>Phenelzine increases vascular sensitivity to sympathetic stimulation<|>7)\n##\n(\"relationship\"<|>DESOGESTREL AND ETHINYL ESTRADIOL<|>GLUCOCORTICOIDS<|>Both affect RAS system leading to hypertension<|>6)\n##\n(\"relationship\"<|>ETHINYL ESTRADIOL AND CYPROTERONE ACETATE<|>GLUCOCORTICOIDS<|>Both affect RAS system leading to hypertension<|>6)\n##\n(\"relationship\"<|>DROSPIRENONE AND ETHINYL ESTRADIOL<|>GLUCOCORTICOIDS<|>Both affect RAS system leading to hypertension<|>6)\n##\n(\"relationship\"<|>BEVACIZUMAB<|>RECOMBINANT HUMAN ERYTHROPOIETIN<|>Both cause vascular effects leading to hypertension<|>5)\n##\n(\"relationship\"<|>SUNITINIB<|>RECOMBINANT HUMAN ERYTHROPOIETIN<|>Both cause vascular effects leading to hypertension<|>5)\n##\n(\"relationship\"<|>SORAFENIB<|>RECOMBINANT HUMAN ERYTHROPOIETIN<|>Both cause vascular effects leading to hypertension<|>5)\n##\n(\"relationship\"<|>AXITINIB<|>RECOMBINANT HUMAN ERYTHROPOIETIN<|>Both cause vascular effects leading to hypertension<|>5)\n##\n(\"relationship\"<|>CORTISONE<|>DIAMMONIUM GLYCYRRHIZINATE<|>Both involve cortisol-mediated effects leading to hypertension<|>6)\n##\n(\"relationship\"<|>PREDNISONE<|>DIAMMONIUM GLYCYRRHIZINATE<|>Both involve cortisol-mediated effects leading to hypertension<|>6)\n##\n(\"relationship\"<|>PREDNISOLONE<|>DIAMMONIUM GLYCYRRHIZINATE<|>Both involve cortisol-mediated effects leading to hypertension<|>6)\n##\n(\"relationship\"<|>DEXAMETHASONE<|>DIAMMONIUM GLYCYRRHIZINATE<|>Both involve cortisol-mediated effects leading to hypertension<|>6)\n##\n(\"relationship\"<|>AZATHIOPRINE<|>BEVACIZUMAB<|>Both affect vascular function leading to hypertension<|>5)\n##\n(\"relationship\"<|>6-MERCAPTOPURINE<|>BEVACIZUMAB<|>Both affect vascular function leading to hypertension<|>5)\n##\n(\"relationship\"<|>CYCLOPHOSPHAMIDE<|>BEVACIZUMAB<|>Both affect vascular function leading to hypertension<|>5)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558813, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1767, "prompt_tokens": 3291, "total_tokens": 5058, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3200}, "prompt_cache_hit_tokens": 3200, "prompt_cache_miss_tokens": 91}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 旋甲状腺素、雷替斯\t交感神经系统兴奋性增强\t应密切监测是否存在心率加快、心 律不齐、血压改变\n抗抑郁药\t舍曲林、氟伏沙明和帕罗西汀、文拉 法辛、瑞波西汀、苯环丙胺、苯乙肼\t　①5-HT的消耗和血中游离 5-HT水平升高 ; ②增 加心肌和血管对交感神经刺激的敏感性而升高血压\t应换用其他种类抗抑郁药或加用 β受体阻滞剂、CCB、ACEI\n口服避孕药\t　去氧孕烯炔雌醇、炔雌醇环丙孕酮、 屈螺酮炔雌醇片\t①增加血容量 ;②对 RAS和交感神经系统的影响 ;\n③对肾血流量的影响 ;④糖脂代谢异常\t应立即停用口服避孕药 ,一般在停 药后 3~6月后血压可恢复\n抗肿瘤药特别是 新型靶向药\tVEGF单克隆抗体(贝伐珠单抗) 、 酪氨酸激酶抑制剂(舒尼替尼、索拉  菲尼和阿西替尼)\t①RAS局部激活 ;②血管收缩 ; ③平滑肌细胞对内 源性血管加压素的敏感性增加 ;④血液黏稠度增加\t应用 β受体阻滞剂、二 氢 吡 啶 类 CCB、ARB,避免应用非二氢吡啶 类 CCB\n糖皮质激素\t　可的 松、泼 尼 松、泼 尼 松 龙、地 塞 米松\t　①可增强 RAS的升压效应 ; ②增强末梢血管对儿 茶酚胺的敏感性 ;③水钠潴溜\t　可选择保钾利尿剂、CCB、β受 体 阻滞剂或 ACEI进行降压 , 同时密 切监测血钾\n促红细胞生成素\t重组人促红细胞生成素\t　①促进内皮素-1释放、血栓烷素 B2合成增加 ;②血 管内皮一氧化氮合成下降 ;③末梢血管异常反应性 收缩\t首选 CCB或 α受体阻滞剂 , 利尿 剂和 ACEI降压不敏感\n免疫抑制剂\t硫唑嘌呤、6-巯基嘌呤、环磷酰胺\t①升高肾脏血管内皮素水平 , 降低肾小球滤过率 ;\n②抑制前列腺素合成和释放\t应用二氢吡啶类 CCB\n植物及矿物药\t甘草类提取物 ,如甘草酸二铵、复方 甘草片 ,胆酸、生胃酮\t　①抑制 11β-羟类固醇脱氢酶的活性 ,皮质醇介导的 盐皮质类固醇产生过多而发生血压升高 ; ②阻止前 列腺素的合成 ;③抑制组胺的合成及释放\t　一般停药后血压即可恢复正常。 需监测血钾水平\n麻黄素类\t麻黄素滴鼻剂 ,麻黄素与氯苯那敏、 苯海拉明等配�\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>SYMPATHETIC NERVOUS SYSTEM<|>ORGANIZATION<|>The sympathetic nervous system's excitability is enhanced, leading to increased heart rate, arrhythmia, and blood pressure changes)\n##\n(\"entity\"<|>ANTIDEPRESSANTS<|>ORGANIZATION<|>Includes drugs like sertraline, fluvoxamine, paroxetine, venlafaxine, reboxetine, phencyclidine, and phenelzine, which affect serotonin levels and increase myocardial and vascular sensitivity to sympathetic stimulation)\n##\n(\"entity\"<|>ORAL CONTRACEPTIVES<|>ORGANIZATION<|>Includes desogestrel and ethinyl estradiol, ethinyl estradiol and cyproterone acetate, drospirenone and ethinyl estradiol, which affect blood volume, RAS, sympathetic nervous system, renal blood flow, and glucose/lipid metabolism)\n##\n(\"entity\"<|>ANTI-TUMOR DRUGS<|>ORGANIZATION<|>Includes VEGF monoclonal antibodies (bevacizumab) and tyrosine kinase inhibitors (sunitinib, sorafenib, and axitinib), which activate RAS, cause vasoconstriction, increase smooth muscle cell sensitivity to vasopressin, and increase blood viscosity)\n##\n(\"entity\"<|>GLUCOCORTICOIDS<|>ORGANIZATION<|>Includes cortisone, prednisone, prednisolone, and dexamethasone, which enhance RAS effects, increase vascular sensitivity to catecholamines, and cause water and sodium retention)\n##\n(\"entity\"<|>ERYTHROPOIETIN<|>ORGANIZATION<|>Recombinant human erythropoietin promotes endothelin-1 release, increases thromboxane B2 synthesis, reduces nitric oxide synthesis, and causes abnormal vascular contraction)\n##\n(\"entity\"<|>IMMUNOSUPPRESSANTS<|>ORGANIZATION<|>Includes azathioprine, 6-mercaptopurine, and cyclophosphamide, which increase renal vascular endothelin levels, reduce glomerular filtration rate, and inhibit prostaglandin synthesis and release)\n##\n(\"entity\"<|>PLANT AND MINERAL MEDICINES<|>ORGANIZATION<|>Includes licorice extracts like diammonium glycyrrhizinate and compound licorice tablets, which inhibit 11β-hydroxysteroid dehydrogenase, leading to cortisol-mediated mineralocorticoid excess, and block prostaglandin and histamine synthesis)\n##\n(\"entity\"<|>EPHEDRINE<|>ORGANIZATION<|>Includes ephedrine nasal drops and combinations with chlorpheniramine or diphenhydramine)\n##\n(\"relationship\"<|>SYMPATHETIC NERVOUS SYSTEM<|>ANTIDEPRESSANTS<|>Antidepressants increase myocardial and vascular sensitivity to sympathetic stimulation<|>7)\n##\n(\"relationship\"<|>ORAL CONTRACEPTIVES<|>GLUCOCORTICOIDS<|>Both affect RAS and sympathetic nervous system, leading to blood pressure changes<|>6)\n##\n(\"relationship\"<|>ANTI-TUMOR DRUGS<|>ERYTHROPOIETIN<|>Both cause vascular effects leading to hypertension<|>5)\n##\n(\"relationship\"<|>GLUCOCORTICOIDS<|>PLANT AND MINERAL MEDICINES<|>Both involve cortisol-mediated effects leading to hypertension<|>6)\n##\n(\"relationship\"<|>IMMUNOSUPPRESSANTS<|>ANTI-TUMOR DRUGS<|>Both affect vascular and renal function, leading to hypertension<|>5)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_44a74d28c08b6714cbba8772af6bf4bfa5567a459645af3077705df5efc37c0e_v2"}